OTX-202 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

11,627 results for “OTX-202”

Mobile App OTX-202 Reduces Suicide Attempts by 58% in High-Risk Psychiatric Patients

Ocular Therapeutix Advances OTX-TKI Phase 3 Trials for Wet AMD with Novel 9-Month Sustained Release Platform

Phase 1 HELIOS Trial Shows Promise for OTX-TKI in Diabetic Retinopathy Treatment

HELIOS Trial Shows Promise: OTX-TKI Demonstrates Positive Results for Diabetic Retinopathy Treatment

Phase 1 HELIOS Trial Shows Promise for OTX-TKI in Non-Proliferative Diabetic Retinopathy

Ocular Therapeutix's OTX-TKI Shows Promise for Diabetic Retinopathy, Phase 3 Trial Planned

OTX-TKI Implant Shows Promise in Reducing Injection Frequency for Wet AMD

OTX-TKI Shows Promise in Stabilizing Non-Proliferative Diabetic Retinopathy in HELIOS Trial

REGENXBIO's RGX-202 DMD Gene Therapy Enters Pivotal Phase 3 Trial

Radiopharm Theranostics' RAD 202 Receives Ethics Approval for Phase 1 Trial in HER2-Expressing Solid Tumors

Page 1 of 354